PBGD-conjugate: improving hemin efficacy in AIP treatment

  • Acute Intermittent Porphyria (AIP) is a rare metabolic liver disorder resulting from mutations in the porphobilinogen deaminase (PBGD), which encodes for the third enzyme involved in the production of heme.

  • Current Standard of Care (SoC) in AIP is intravenous hemin administration, which provides exogenous heme for the negative feedback inhibition of ALAS, decreasing further ALA and PBG production.  

  • Hemin treatment effect is slow and requires 3 or 4 daily infusions. Moreover, side effects as headache, thrombophlebitis, hepatosiderosis and decreasing sensitivity should be considered.

  • A new molecule rhPBGD‐conjugate has been developed with the following properties:  

    • metabolizes serum PBG.

    • subcutaneous administration.

    • increased half‐life in circulation than previous failed approaches rhPBGD (Zymenex A/S).

  • Indication: combined administration with hemin in AIP acute attacks.

>> Download information

Research Programs

Research programs in which you can participate with CIMA

CIMA Research Programs and Agreements [PDF]

"CIMA Lab Diagnostics"

Its objective is to optimize the range of genetic and immunophenotypic diagnoses carried out in different laboratories of the University of Navarra with the highest level of quality and innovation.

Go to companies

Contact us:

Center for Applied Medical Research (CIMA)
Avenida Pío XII, 55
31008 Pamplona

+34 948 194700